Out-of-pocket costs for cancer care keep climbing

Cancerpatients already have a lot to deal with emotionally and physically. But research shows that insured patients under 65 are also paying more for their treatments out-of-pocket than ever bef

Updated on: December 18,2023 10

Out-of-pocket costs for cancer care keep climbing

Cancerpatients already have a lot to deal with emotionally and physically. But research shows that insured patients under 65 are also paying more for their treatments out-of-pocket than ever bef

Updated on:December 18,2023 10

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on: October 24,2023 77

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on:October 24,2023 77

A new mechanism of drug resistance discovered for breast cancer

by Universita Cattolica del Sacro CuoreEmergence of CSCs following IFN-I treatment.a, Multiparametric flow cytometry analysis of the illustrated CSC surface markers in MCA205 and AT3 cells treat

Updated on: December 21,2023 13

A new mechanism of drug resistance discovered for breast cancer

by Universita Cattolica del Sacro CuoreEmergence of CSCs following IFN-I treatment.a, Multiparametric flow cytometry analysis of the illustrated CSC surface markers in MCA205 and AT3 cells treat

Updated on:December 21,2023 13

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on: October 24,2023 49

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on:October 24,2023 49

Large study links sustained weight loss to reduced breast cancer risk

byAmerican Cancer SocietyCredit: CC0 Public DomainA large new study finds that women who lost weight after age 50 and kept it off had a lower risk of breast cancer than women whose weight remain

Updated on: December 22,2023 19

Large study links sustained weight loss to reduced breast cancer risk

byAmerican Cancer SocietyCredit: CC0 Public DomainA large new study finds that women who lost weight after age 50 and kept it off had a lower risk of breast cancer than women whose weight remain

Updated on:December 22,2023 19

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

byThe Mount Sinai HospitalCredit: Unsplash/CC0 Public DomainA clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improve

Updated on: October 23,2023 164

Adding immunotherapy to chemotherapy regimen improves survival in metastatic bladder cancer patients

byThe Mount Sinai HospitalCredit: Unsplash/CC0 Public DomainA clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improve

Updated on:October 23,2023 164

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on: October 24,2023 32

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on:October 24,2023 32

Healthy diets linked to better outcomes in colorectal cancer

byAmerican Cancer SocietyCredit: CC0 Public DomainColorectal cancer patients who followed healthy diets had a lower risk of death from colorectal cancer and all causes, even those who improved t

Updated on: December 18,2023 13

Healthy diets linked to better outcomes in colorectal cancer

byAmerican Cancer SocietyCredit: CC0 Public DomainColorectal cancer patients who followed healthy diets had a lower risk of death from colorectal cancer and all causes, even those who improved t

Updated on:December 18,2023 13

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on: October 24,2023 2

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on:October 24,2023 2

Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainPatients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anem

Updated on: December 19,2023 10

Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis

byUniversity of Texas M. D. Anderson Cancer CenterCredit: Unsplash/CC0 Public DomainPatients with myelofibrosis had clinically significant improvement in disease-related symptoms, including anem

Updated on:December 19,2023 10

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on: October 12,2023 6

EMA Accepts Marketing Application for Odronextamab in R/R DLBCL or Follicular Lymphoma

August 17, 2023Chris RyanThe European Medicines Agency has accepted a marketing authorization application seeking the approval of odronextamab for the treatment of adult patients with relapsed/refract

Updated on:October 12,2023 6

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on: October 17,2023 178

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on:October 17,2023 178